These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36044227)

  • 21. Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy.
    Musoro JZ; Sodergren SC; Coens C; Pochesci A; Terada M; King MT; Sprangers MAG; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
    Colorectal Dis; 2020 Dec; 22(12):2278-2287. PubMed ID: 32767619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer.
    Musoro JZ; Coens C; Fiteni F; Katarzyna P; Cardoso F; Russell NS; King MT; Cocks K; Sprangers MA; Groenvold M; Velikova G; Flechtner HH; Bottomley A;
    JNCI Cancer Spectr; 2019 Sep; 3(3):pkz037. PubMed ID: 32328553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.
    Koller M; Musoro JZ; Tomaszewski K; Coens C; King MT; Sprangers MAG; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A
    Lung Cancer; 2022 May; 167():65-72. PubMed ID: 35413526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument.
    Yost KJ; Sorensen MV; Hahn EA; Glendenning GA; Gnanasakthy A; Cella D
    Value Health; 2005; 8(2):117-27. PubMed ID: 15804320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-Reported Outcome Measures in Cardiovascular Disease: An Evidence Map of the Psychometric Properties of Health Status Instruments.
    Chew DS; Whitelaw S; Vaduganathan M; Mark DB; Van Spall HGC
    Ann Intern Med; 2022 Oct; 175(10):1431-1439. PubMed ID: 36122377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience.
    Yost KJ; Eton DT
    Eval Health Prof; 2005 Jun; 28(2):172-91. PubMed ID: 15851772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review.
    Ousmen A; Touraine C; Deliu N; Cottone F; Bonnetain F; Efficace F; Brédart A; Mollevi C; Anota A
    Health Qual Life Outcomes; 2018 Dec; 16(1):228. PubMed ID: 30537955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Responsiveness and minimally important difference of SF-6D and EQ-5D utility scores for the treatment of pelvic organ prolapse.
    Harvie HS; Honeycutt AA; Neuwahl SJ; Barber MD; Richter HE; Visco AG; Sung VW; Shepherd JP; Rogers RG; Jakus-Waldman S; Mazloomdoost D;
    Am J Obstet Gynecol; 2019 Mar; 220(3):265.e1-265.e11. PubMed ID: 30471259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishing Minimal Important Differences for the VR-12 and SANE Scores in Patients Following Treatment of Rotator Cuff Tears.
    Zhou L; Natarajan M; Miller BS; Gagnier JJ
    Orthop J Sports Med; 2018 Jul; 6(7):2325967118782159. PubMed ID: 30090834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults.
    Kendrick T; El-Gohary M; Stuart B; Gilbody S; Churchill R; Aiken L; Bhattacharya A; Gimson A; Brütt AL; de Jong K; Moore M
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011119. PubMed ID: 27409972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal important differences of the SRS-22 Patient Questionnaire following surgical treatment of idiopathic scoliosis.
    Bagó J; Pérez-Grueso FJ; Les E; Hernández P; Pellisé F
    Eur Spine J; 2009 Dec; 18(12):1898-904. PubMed ID: 19533179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimum important difference for validated instruments in women with urge incontinence.
    Dyer KY; Xu Y; Brubaker L; Nygaard I; Markland A; Rahn D; Chai TC; Stoddard A; Lukacz E;
    Neurourol Urodyn; 2011 Sep; 30(7):1319-24. PubMed ID: 21563210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unravelling the mystery of the 'minimum important difference' using practical outcome measures in chronic respiratory disease.
    Houchen-Wolloff L; Evans RA
    Chron Respir Dis; 2019; 16():1479973118816491. PubMed ID: 30789024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic Review of Patient-Reported Outcome Measures in Graft-versus-Host Disease.
    Kilgour JM; Wali G; Gibbons E; Scherwath A; Barata Badiella A; Peniket A; Schoemans H; Matin RN;
    Biol Blood Marrow Transplant; 2020 May; 26(5):e113-e127. PubMed ID: 32028026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Utility of Patient-Reported Outcome Measurement Information System Domain Scales.
    Lapin B; Thompson NR; Schuster A; Katzan IL
    Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004753. PubMed ID: 30587028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches.
    Yost KJ; Cella D; Chawla A; Holmgren E; Eton DT; Ayanian JZ; West DW
    J Clin Epidemiol; 2005 Dec; 58(12):1241-51. PubMed ID: 16291468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma.
    Reni M; Braverman J; Hendifar A; Li CP; Macarulla T; Oh DY; Riess H; Tempero M; Lu B; Marcus J; Joshi N; Botteman M; Dueck AC
    Ann Surg Oncol; 2021 Nov; 28(12):7545-7554. PubMed ID: 33813673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating minimal important differences for the FACT-Melanoma quality of life questionnaire.
    Askew RL; Xing Y; Palmer JL; Cella D; Moye LA; Cormier JN
    Value Health; 2009; 12(8):1144-50. PubMed ID: 19558579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A point of minimal important difference (MID): a critique of terminology and methods.
    King MT
    Expert Rev Pharmacoecon Outcomes Res; 2011 Apr; 11(2):171-84. PubMed ID: 21476819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.